Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy

International Journal of Clinical Oncology

Volumn 20, Issue 1, 2015, Pages 105-110

  Akutsu, Noriyuki ^a   Sasaki, Shigeru ^a   Takagi, Hideyasu ^a   Motoya, Masayo ^a   Shitani, Masahiro ^a   Igarashi, Mai ^a   Hirayama, Daisuke ^a   Wakasugi, Hideki ^a   Yamamoto, Hiroyuki ^a   Kaneto, Hiroyuki ^b   Yonezawa, Kazuhiko ^c   Yawata, Atsushi ^d   Adachi, Takeya ^e   Hamamoto, Yasuo ^f   Shinomura, Yasuhisa ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b Muroran City General Hospital   (Japan)

^c Kushiro City General Hospital   (Japan)

^d Department of Urology Hakodate Goryoukaku Hospital   (Japan)

^e Otaru City General Hospital   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Hypertension; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; SORAFENIB;

AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; DISEASE COURSE; FEMALE; HUMAN; HYPERTENSION; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 84939874793     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-014-0691-5     Document Type: Article

References (24)

1. Llovet J, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 359:378–390
2. Cheng A-L, Kang Y-K, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
3. Wilhelm S, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109
4. Lencioni R, Llovet J (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60
5. Schneider B, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672–4678
6. Scartozzi M, Galizia E, Chiorrini S et al (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227–230
7. Österlund P, Soveri L-M, Isoniemi H et al (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104:599–604
8. Dewdney A, Cunningham D, Barbachano Y et al (2012) Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer 106:1718–1721
9. Tahover E, Uziely B, Salah A et al (2013) Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 30:327
10. Rutkowski P, Bylina E, Klimczak A et al (2012) The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure: one institution study. BMC Cancer 12:107
11. George S, Reichardt P, Lechner T et al (2012) Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 23:3180–3187
12. Estfan B, Byrne M, Kim R (2013) Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol 36:319–324
13. Schuster C, Eikesdal H, Puntervoll H et al (2012) Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS ONE 7:e38364
14. Rixe O, Billemont B, Izzedine H (2007) Hypertension as a predictive factor of sunitinib activity. Ann Oncol 18:1117
15. Rini B, Cohen D, Lu D et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763–773
16. Bono P, Rautiola J, Utriainen T et al (2011) Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 50:569–573
17. Szmit S, Langiewicz P, Złnierek J et al (2012) Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 35:18–25
18. Szmit S, Zaborowska M, Waśko Grabowska A et al (2012) Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. Kidney Blood Press Res 35:468–476
19. Funakoshi T, Latif A, Galsky MD (2013) Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 27:601–611
20. Mir O, Coriat R, Cabanes L et al (2011) An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 16:1325–1332
21. Spano J-P, Chodkiewicz C, Maurel J et al (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371:2101–2108
22. Bruix J, Raoul J-L, Sherman M et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57:821–829
23. Cheng A-L, Guan Z, Chen Z et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer 48:1452–1465
24. Humphreys B, Atkins M (2009) Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res 15:5947–5949